ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 03/23/2026 at 21:05, 4 months 14 days ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Abivax reports full year 2025 financial results and key business updates, including safety updates, pivotal Phase 3 trial progress, senior leadership appointments, and upcoming milestones. Strong cash position and strategic plans highlighted

Financial Results Abivax Phase 3 Trial Leadership Appointments Business Updates
BRIEF

published on 02/26/2026 at 18:05, 5 months 8 days ago

ABIVAX : Actualisation sur le Capital Social et les Droits de Vote

Euronext Paris Droits De Vote Capital Social Actions Abivax
BRIEF

published on 02/26/2026 at 18:05, 5 months 8 days ago

ABIVAX: Update on Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights Shares Abivax
PRESS RELEASE

published on 02/26/2026 at 18:00, 5 months 8 days ago

ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.
ABIVAX communique le nombre d'actions et de droits de vote au 31 janvier 2026. Informations réglementaires conformes au Code de Commerce et au règlement de l'AMF

Droits De Vote Actions AMF Abivax Réglementaire
BRIEF

published on 02/21/2026 at 12:05, 5 months 13 days ago

Abivax Unveils Promising Obefazimod Data at ECCO 2026

Obefazimod Clinical Efficacy Safety Profile Inflammatory Bowel Disease Anti-Fibrotic Activity
BRIEF

published on 02/21/2026 at 12:05, 5 months 13 days ago

Abivax dévoile des données prometteuses sur l'obefazimod lors du salon ECCO 2026

Obefazimod Efficacité Clinique Profil De Sécurité Maladie Inflammatoire De L'intestin Activité Antifibrotique
PRESS RELEASE

published on 02/21/2026 at 12:00, 5 months 13 days ago

Abivax présente, au Congrès de l’ECCO 2026, les premières preuves d’une activité antifibrotique d'obefazimod, ainsi que de nouvelles analyses de son efficacité et de sécurité dans les MICI
Abivax présente de nouvelles données sur l'efficacité clinique et l'activité antifibrotique d'obefazimod dans le traitement des maladies inflammatoires chroniques de l'intestin au Congrès de l'ECCO 2026

Abivax Obefazimod Maladie De Crohn Maladies Inflammatoires Fibrose
PRESS RELEASE

published on 02/21/2026 at 12:00, 5 months 13 days ago

Abivax présente, au Congrès de l’ECCO 2026, les premières preuves d’une activité antifibrotique d'obefazimod, ainsi que de nouvelles analyses de son efficacité et de sécurité dans les MICI
Abivax présente les preuves d’une activité antifibrotique d'obefazimod et de nouvelles analyses de son efficacité et de sécurité dans les MICI au Congrès de l’ECCO 2026

Abivax Obefazimod Sécurité Efficacité Clinique Activité Antifibrotique
PRESS RELEASE

published on 02/21/2026 at 12:00, 5 months 13 days ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax presents first evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026

Abivax Obefazimod Clinical Efficacy Inflammatory Bowel Disease Anti-fibrotic
BRIEF

published on 01/26/2026 at 18:05, 6 months 11 days ago

ABIVAX: Share capital and voting rights as of December 31, 2025

Voting Rights Biotechnology Actions AMF Abivax

Published on 08/07/2026 at 00:45, 4 hours 29 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 5 hours 59 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 6 hours 59 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 7 hours 9 minutes ago

Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 7 hours 14 minutes ago

Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE

View all ACCESSWIRE

Published on 08/06/2026 at 22:50, 6 hours 24 minutes ago

Amrize Reports Second Quarter 2026 Results
Published on 08/06/2026 at 22:15, 6 hours 59 minutes ago

BIRKENSTOCK SEEKS TO FILL VACANCY IN THE BOARD OF DIRECTORS WITH AN INDEPENDENT DIRECTOR, FOLLOWING ALEXANDRE ARNAULT'S RESIGNATION DUE TO PROFESSIONAL COMMITTMENTS
Published on 08/06/2026 at 21:45, 7 hours 29 minutes ago

FP Markets Analysis: Japanese Yen at a Crossroads as Markets Weigh Next Move
Published on 08/06/2026 at 19:05, 10 hours 9 minutes ago

Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEO
Published on 08/06/2026 at 18:24, 10 hours 49 minutes ago

EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026

View all EQS

Published on 08/06/2026 at 18:26, 10 hours 48 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 18:26, 10 hours 48 minutes ago

Air Liquide droits de vote au 31 juillet 2026
Published on 08/06/2026 at 17:46, 11 hours 28 minutes ago

Déclaration des droits de vote à fin juillet 2026
Published on 08/06/2026 at 17:45, 11 hours 29 minutes ago

Déclaration des droits de vote à fin juillet 2026
Published on 08/06/2026 at 17:45, 11 hours 29 minutes ago

Declaration of voting rights at the end of July 2026

View all LES ECHOS COMFI WIRE

News